TrialBreast cancer research and treatment2021

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

Beverly Moy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.